Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets. The platform aims to improve clinical trial patient selection and expand the set of viable cancer targets in drug development.
4 investors
NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore. Its pipeline addresses neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS/MND) and Parkinson's, with lead candidate NRG5051 entering a first-in-human trial.
4 investors
Numerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
4 investors
NΕ«mi uses cell culture technology to produce a new form of nutrition, aiming to replicate the benefits of breast milk as an alternative for parents and infants, with potential applications across other age groups. It operates in the food and biotech space focused on human nutrition and health.
4 investors
NunaBio manufactures high-complexity DNA constructs from challenging sequences up to production-scale volumes using a modular, cell-free "DNA micro-foundry" platform. It provides software-orchestrated, distributed DNA manufacturing infrastructure for producing complex DNA without process redevelopment.
4 investors
Nuritas uses a proprietary AI platform, the Nuritas Magnifier, to discover and clinically validate bioactive peptide ingredients derived from natural sources. It develops formulation-ready ingredients such as PeptiStrong for food, supplement, and health product companies.
4 investors
Nuvation Bio is a global oncology company developing and commercializing novel therapies for difficult-to-treat cancers, targeting indications where conventional treatments have failed. Its pipeline of therapeutic candidates addresses drug resistance and limited efficacy of current cancer therapies.
4 investors
NVision develops quantum computing and quantum-enhanced sensing platforms based on quantum spin control in organic molecules, with focus on healthcare applications including drug development and disease treatment.
4 investors
Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases. Its lead therapy is in Phase 3 clinical trials for wet AMD, with additional focus on diabetic retinopathy.
4 investors
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance. It focuses on improving treatment outcomes for patients living with breast cancer.
4 investors
OMass uses native mass spectrometry, proprietary biochemistry and custom chemistry to study drug targets and their interactions with their native biological environment outside the confounding complexity of the cell. It operates in drug discovery within the biotech/pharmaceutical sector.
4 investors
Ona Therapeutics is a biotechnology company developing first-in-class antibody drug conjugates (ADCs) and antibody therapies targeting the molecular biology of treatment-refractory advanced cancers. Spun out of ICREA and IRB, it focuses on precision therapeutics for patients with advanced solid tumors such as breast cancer who have no remaining treatment options.
4 investors
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
4 investors
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
4 investors
One Zyme is an AI-native intelligence platform that aggregates scientific, clinical, regulatory, funding, patent, deal, and conference signals into a shared knowledge graph for life sciences teams. It provides AI agents and nine intelligence workflows serving business development, competitive intelligence, R&D, commercial, and biopharma vendor teams across the pharma and biotech industry.
4 investors
Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space. It is backed by healthcare-focused investors and announced a Series D financing in October 2024.
4 investors
Orbis Diagnostics is developing a point-of-care diagnostics platform that produces blood test results from a single fingerstick of blood. The product targets clinical blood testing in the medical diagnostics field.
4 investors
Orbit Discovery is a drug discovery company that participates in industry conferences focused on peptide therapeutics and GPCR-targeted drug discovery. The available page content does not describe its specific products or platform in detail.
4 investors
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
4 investors
Orchid offers whole genome sequencing-based genetic screening of embryos during IVF as well as preconception testing for couples, analyzing DNA to identify predispositions to monogenic diseases, chromosomal abnormalities, and polygenic risks. It serves prospective parents and IVF patients, delivering reports reviewed by board-certified genetic counselors.
4 investors
Osmind is a public benefit corporation developing technology and research infrastructure to accelerate evidence-based mental health treatments, including therapies like ketamine, and to improve patient access to care.
4 investors
Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms. The company operates as a clinical-stage biotech firm manufacturing and distributing cellular therapeutics for patients with organ and tissue diseases.
4 investors
Output builds generative AI models trained on biological data to discover and develop medicines. The company focuses on applying large biological models to improve diagnosis, treatment, and disease prevention.
4 investors
P2 Science develops green chemistry platform technologies (including its PIOz ozonolysis and PICE polymerization processes) that convert renewable, plant-based oils into functional intermediates, specialty ingredients, and polymers. Its products serve the flavors, fragrances, and beauty/cosmetics industries, with R&D in Woodbridge, CT and manufacturing in Naugatuck, CT.
4 investors